The Effect of L-dopa on Postural Stability in Parkinson's Disease Patients

被引:4
|
作者
Wilczynski, Jacek [1 ]
Habik, Natalia [2 ]
机构
[1] Jan Kochanowski Univ, Fac Med & Hlth Sci, Dept Posturol Hearing & Balance Rehabil, PL-25317 Kielce, Poland
[2] Jan Kochanowski Univ, Fac Med & Hlth Sci, PL-25317 Kielce, Poland
来源
APPLIED SCIENCES-BASEL | 2019年 / 9卷 / 03期
关键词
L-dopa; Parkinson's disease; Postural Stability Test; INTESTINAL GEL; LEVODOPA; GAIT; STIMULATION; INSTABILITY; BALANCE; PEOPLE;
D O I
10.3390/app9030409
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The aim of the study was to evaluate the effects of L-dopa on postural stability in Parkinson's disease patients. In the study, we examined a group of 13 patients, members of the Parkinson's Association. The majority of subjects were women: 8 (61.538%), while 5 (38.462%) were men. These were patients with advanced, idiopathic Parkinson's disease. The study was performed at the Posturology Laboratory of the Faculty of Medicine and Health Sciences, UJK, Kielce (Poland). The duration of the illness was longer than 5 years. The daily L-dopa dose was between 600 and 1000 mg/d. Patients were tested for postural stability prior to taking the morning dose and again, 1 h after the 200-mg dose (Madopar 250 Tablets). The Biodex Balance System was applied in order to perform Postural Stability Testing. No statistically significant differences were found for the distribution of postural stability results before or after L-dopa administration. Nonetheless, it should be noted that all variables in the Postural Stability Test were slightly improved following L-dopa administration. The highest percentage (% Time in Zone) was noted in Zone A (the best), before (85.77%) and after L-dopa administration (95.23%). The highest % Time in Quadrant was in Quadrant IV (right posterior) both before (41.43%) and after L-dopa administration (49.54%). When comparing the distribution of postural stability variables before and after L-dopa administration, there were no significant differences between women and men.
引用
下载
收藏
页数:10
相关论文
共 50 条
  • [41] Paradoxical response to L-dopa and apomorphine in the Parkinson's disease
    García-Soldevilla, MA
    Puertas, I
    Barcenilla, B
    Sayed, Y
    García-Albea, E
    Jiménez-Jiménez, FJ
    MOVEMENT DISORDERS, 2002, 17 : S96 - S96
  • [42] Parkinson's disease, L-DOPA, and endogenous morphine: A revisit
    Stefano, George B.
    Mantione, Kirk J.
    Kralickova, Milena
    Ptacek, Radek
    Kuzelova, Hana
    Esch, Tobias
    Kream, Richard M.
    MEDICAL SCIENCE MONITOR, 2012, 18 (08): : RA133 - RA137
  • [43] L-DOPA for Parkinson's disease-a bittersweet pill
    Lane, Emma L.
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2019, 49 (03) : 384 - 398
  • [44] L-DOPA: A scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski, Janusz
    Nistico, Robert
    Berretta, Nicola
    Guatteo, Ezia
    Bernardi, Giorgio
    Mercuri, Nicola B.
    PROGRESS IN NEUROBIOLOGY, 2011, 94 (04) : 389 - 407
  • [45] L-dopa impairs associative learning in Parkinson's disease
    Shohamy, D
    Myers, CE
    Onlaor, S
    Gluck, MA
    JOURNAL OF COGNITIVE NEUROSCIENCE, 2002, : 84 - 84
  • [46] Parkinson's disease: Progression and mortality in the L-DOPA era
    DiRocco, A
    Molinari, SP
    Kollmeier, B
    Yahr, MD
    PARKINSON'S DISEASE, 1996, 69 : 3 - 11
  • [47] Plasma homocysteine and L-DOPA metabolism in patients with Parkinson disease
    Blandini, F
    Fancellu, R
    Martignoni, E
    Mangiagalli, A
    Pacchetti, C
    Samuele, A
    Nappi, G
    CLINICAL CHEMISTRY, 2001, 47 (06) : 1102 - 1104
  • [48] Effect of liposomal L-Dopa on the Parkinson's syndrome in mice
    Kucheryanu, VG
    Yurasov, VV
    Kryzhanovskii, GN
    Nikushkin, EV
    Zhigaltsev, IV
    Kaplun, VP
    Shvets, VI
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 1997, 123 (01) : 24 - 27
  • [49] Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites
    Davidson, D. F.
    Grosset, K.
    Grosset, D.
    ANNALS OF CLINICAL BIOCHEMISTRY, 2007, 44 : 364 - 368
  • [50] Safety and tolerability profile of preladenant as an adjunct to L-dopa in patients with Parkinson's disease
    Pourcher, E.
    Micheli, F.
    Mok, V.
    Onofrj, M.
    Hauser, R. A.
    Huyck, S.
    Wolski, K.
    Cantillon, M.
    MOVEMENT DISORDERS, 2009, 24 : S274 - S274